Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureSudhir Nair, Mayuri Inchanalkar, Rinal Chavdaa, Vijay Patil, Vanita Noronha, Kumar Prabhash, Abhishek Mahajan, Nilesh Sable, Amit Janu, Swapnil Rane, Asawari Patil, Shwetabh Sinha, V.V. Sameema, Kavita Sonawane, Deepa Nair, J.P. Agarwal, Sarbani Laskar, Tejpal Gupta, Anil K D’Cruz, Devendra Chaukar, Prathmesh S. Pai, Manoj Mahimkar, Pankaj Chaturvedi
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck
10.1158/1078-0432.ccr-03-0677 · 2004
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
10.1200/jco.2003.10.051 · 2003
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
2016
Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer
10.1158/1078-0432.ccr-19-3997 · 2020
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase Ib and pharmacokinetic study
10.1158/1940-6207.capr-13-0215 · 2013
Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer
10.1056/nejmoa2415434 · 2025
10.1158/1078-0432.ccr-12-3149
10.1158/1078-0432.ccr-12-3149
Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography
10.1097/md.0000000000004874 · 2016
Time-to-treatment in oral cancer: causes and implications for survival
10.3390/cancers13061321 · 2021
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020
Delay in seeking specialized care for oral cancers: Experience from a tertiary cancer center
10.4103/0019-509x.137934 · 2014
10.4322/acr.2021.251
10.4322/acr.2021.251
Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma
10.2174/156800909790192437 · 2009
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer
10.1002/cncr.29480 · 2015
No additional external references are available.